GLYCIPHAGE-P15® Tablets

No Image Found
Composition:

GLYCIPHAGE-P15® :  

Each uncoated bilayered tablet contains:

  • Metformin Hydrochloride I.P.  ……… 500 mg (in sustained-release form)
  • Pioglitazone Hydrochloride I.P. equivalent to Pioglitazone ……………………………………….………….. 15 mg
  • Excipients …………………….……… q.s.

Description

  • Insulin resistance in the liver and muscles is a key cause of Type 2 Diabetes.                                
  • Metformin lowers blood sugar by reducing hepatic glucose production, intestinal absorption, and improving insulin sensitivity.
  • Pioglitazone in GLYCIPHAGE-P15® is an "insulin sensitizer" enhances insulin sensitivity and improves glucose uptake in muscles and fat, with added cardiometabolic benefits.
  • Together, they work through complementary mechanisms to provide better glycaemic control, insulin sensitivity, and support beta-cell function more effectively than either drug alone.

Indications

  • Monotherapy: As adjunct to diet and exercise to improve glycaemic control in patients with Type 2 diabetes.
  • Combination Therapy: Concomitantly with sulphonylurea or insulin to improve glycaemic control in adults (17 years of age and older).

Dosage

  • Dosage should be individualized on the basis of both effectiveness and tolerability while not exceeding the maximum recommended daily dose of individual components.
  • It should be given once daily with meals and should be started at a low dose.
  • The usual starting dose is one tablet of GLYCIPHAGE-P15® once daily. The dose may be increased to one to three tablets of GLYCIPHAGE-P15® if adequate response is not observed by 12 weeks.
  • The maximum recommended dose for metformin sustained-release is 2000 mg daily. The maximum recommended daily dose for Pioglitazone is 45 mg in adults.